Seb

NEW ON ATOMIC IBD (link to full article below) Eight years ago I had the idea of combining ustekinumab and vedolizumab after anti-TNF failure in Crohn's disease. No one would have funded it then. Now J&J, AbbVie, Spyre, Lilly and Takeda are all testing versions of that idea. Part 1 of my combination therapy series is up on Atomic IBD, and it asks the obvious question: do two advanced therapies beat one? Every estimate so far leans towards the combination (image 1 below). But no combination of two advanced therapies has yet beaten the best single drug on a primary or multiplicity-controlled endpoint, across a whole trial population, in a blinded randomised trial. The gains that clear zero come in the most refractory patients. In DUET-CD, after two or more failed therapy classes, 49% were in clinical remission at week 48 on high-dose JNJ-4804 v 27% on guselkumab, in an exploratory subgroup. In TARGET-CD, endoscopic remission at week 24 was 41% on ABBV-466 v 22% and 20% on each drug alone, open label. The piece also covers why a two-in-one injection is hard to make and to prove, which pairs are being tested and why, whether two biosimilars could take on the branded combinations, and four different ways to combine. Only three of these trials are in phase 3 (image 2 below). VICTRIVA reads out in 2027, then COMMIT and DUET ENCORE, the first phase 3 of a two-in-one injection, in 2028. Part 2 turns to oral combinations, including whether an IBD polypill is realistic. Link to the full article in the reply.

A true privilege to represent the @AmerGastroAssn w AGA President @BCryer & review Best of #IBD of #DDW26 at @my_ueg ✅FUZION ✅DUET-CD ✅ARTEMIS-UC ✅COMPARE-IBD ✅MIMIMISE ✅Summary 👇🏽 Congrats @joostphdrenth @schattenbergJ for a fabulous #UEGWeek w 🌟research & faculty🌟

ANTHEM-UC Phase 2b study presented by Britta Siegmund! Icotrokinra, a first-in-class targeted oral IL-23 receptor peptide, demonstrated remarkable histologic and endoscopic efficacy in UC through Week 28. A huge step forward for oral targeted therapies! #IBD #UEGWeek @MyueGodo

Excited to be part of #AFFIRM presented #UEGWeek @my_ueg #RISA SC induction 🔺At wk12 , in AT naïve/ AT-exposed 🩺Clinical Remissn 73/45% 🔦Endo improvmt 61/34% 🔦Endo remission 45/18%

The most anticipated study in #IBD over last few years #VERDICT being presented at #UEGW2026 @my_ueg Barcelona in 5 minutes @vipuljairath @alimentiv @IbdHull @TakedaPharmaUK